Michael Fay

Professor Michael Fay is the Foundation Chair at the University of Newcastle's Mark Hughes Foundation Centre for Brain Cancer Research. He is a practicing Radiation Oncologist at GenesisCare in Newcastle and Maitland, with extensive clinical trials experience and international collaborations in Australia, Canada, UK, and Germany.

Education includes a

• PhD in Theranostics and Radiation Oncology (University of Queensland, 2020)
• MBBS (University of Otago, New Zealand)

His research focuses on precision radiation treatment for brain cancer, targeting receptor-based theranostics, radiation resistance mechanisms, and DNA damage response. Recent work examines ATR inhibition, PSMA expression, and immune profiling in glioblastoma.

Key article trends include

• Targeting DNA repair pathways to overcome glioblastoma resistance
• Advancing PET/MRI for diagnostic accuracy
• Characterizing tumour-immune interactions
• Optimizing radiation therapy margins
• Investigating blood-based biomarkers like EphA2 and lymphopenia

Scientific Awards:

• FRANZCR (2003)
• FRACP (2003)

Active in clinical trial design and multi-modal treatment strategies, with funding from the Mark Hughes Foundation, Hunter Medical Research Institute, and Tour de Cure. Leads the Patient Experience stream at the MHF Centre, collaborating with Cath Adams and Paul Tooney.